# Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients

> **NCT03509584** · PHASE1 · TERMINATED · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 6 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **RADIATION:** hypofractionated radiotherapy
- **DRUG:** nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03509584
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-07
- **Primary completion:** 2019-07-02
- **Final completion:** 2019-07-02
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** SAFETY
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03509584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03509584, "Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03509584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*